Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Operating Expenses (2020 - 2025)

SAB Biotherapeutics (SABS) has disclosed Operating Expenses for 6 consecutive years, with $15.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses rose 55.78% year-over-year to $15.8 million, compared with a TTM value of $49.0 million through Dec 2025, up 10.67%, and an annual FY2025 reading of $49.0 million, up 10.67% over the prior year.
  • Operating Expenses was $15.8 million for Q4 2025 at SAB Biotherapeutics, up from $12.7 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $73.6 million in Q4 2021 and bottomed at $256847.0 in Q2 2021.
  • Average Operating Expenses over 5 years is $14.7 million, with a median of $11.4 million recorded in 2022.
  • The sharpest move saw Operating Expenses skyrocketed 817655.34% in 2021, then plummeted 86.38% in 2022.
  • Year by year, Operating Expenses stood at $73.6 million in 2021, then tumbled by 86.38% to $10.0 million in 2022, then soared by 91.39% to $19.2 million in 2023, then tumbled by 47.21% to $10.1 million in 2024, then soared by 55.78% to $15.8 million in 2025.
  • Business Quant data shows Operating Expenses for SABS at $15.8 million in Q4 2025, $12.7 million in Q3 2025, and $9.7 million in Q2 2025.